Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and risk factors
-
30 min
1. Epidemiology of COPD- Dr. David Mannino
-
36 min
2. COPD in never smokers- Dr. Sundeep Salvi
-
43 min
3. Genetics of chronic obstructive pulmonary disease (COPD)- Prof. Martin Tobin
- Phenotypes of COPD
-
44 min
4. COPD and asthma: similarities and differences- Prof. Peter Barnes
- Pathophysiology and mechanisms of COPD
-
43 min
5. The pathology of chronic obstructive pulmonary disease- Prof. James Hogg
-
63 min
6. The continuum of COPD: a physiological perspective- Prof. Denis O'Donnell
-
47 min
7. Inflammatory and immune mechanisms in COPD- Prof. Peter Barnes
-
44 min
8. Mechanisms of COPD exacerbations and relation to exacerbation therapy- Prof. Wisia Wedzicha
-
39 min
9. Protease-antiprotease balance- Prof. Robert Stockley
- Therapy and management
-
42 min
10. Updates in chronic obstructive pulmonary disease (COPD)- Dr. Omar S. Usmani
-
45 min
11. Long-acting bronchodilators in COPD- Prof. Bart Celli
-
54 min
12. Treatment of COPD exacerbations- Prof. Antonio Anzueto
-
25 min
13. Pulmonary rehabilitation: history, promise and problems- Prof. Richard Casaburi
-
29 min
14. Lung volume reduction: advances in COPD- Dr. Nick Hopkinson
-
35 min
15. New pharmacological therapies for COPD- Prof. Peter Barnes
-
32 min
16. The Salford lung study in COPD- Dr. Dave Leather
- COPD case studies
-
11 min
17. COPD treatment case I: COPD with “bronchitis attacks”- Dr. Janwillem Kocks
-
13 min
18. COPD treatment case II: COPD with asthma as child- Dr. Janwillem Kocks
-
12 min
19. COPD treatment case III: COPD with pre-diabetes- Dr. Janwillem Kocks
-
48 min
20. Tailoring care for advanced COPD- Prof. Wissam Chatila
- Archived Lectures *These may not cover the latest advances in the field
-
59 min
21. Alpha-1 antitrypsin deficiency: state of the art- Dr. Jamie Stoller
-
34 min
22. Oxidative stress in COPD- Prof. William MacNee
-
24 min
23. Managing co-morbidity in COPD- Dr. John Hurst
-
40 min
24. Clinical phenotypes of COPD- Prof. Jørgen Vestbo
-
27 min
25. Pulmonary rehabilitation: focusing on rehabilitative exercise- Prof. Richard Casaburi
-
36 min
26. Genetics of COPD- Prof. Ian Hall
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture outline
- Alpha 1-antitrypsin (AAT) deficiency
- My disclosures of significant relationships
- A registry of patients with AAT deficiency
- Primary objective of the registry
- American thoracic society documents
- AAT: history
- First description of AAT deficiency
- Dr. Eriksson and Dr. Stoller
- Medline citations for the term AAT deficiency
- Epidemiology of AAT deficiency
- Prevalence of AAT deficiency
- Prevalence of PI*Z AAT deficiency
- AAT deficiency is frequently undiagnosed
- Most with AAT deficiency escape detection
- Alpha 1-antitrypsin deficiency is under-recognized
- A1AT-deficient readers survey of alpha 1 news (1)
- A1AT-deficient readers survey of alpha 1 news (2)
- Diagnostic delay interval by year of diagnosis
- Trends in diagnosing AAT deficiency
- Physiology of AAT and pathophysiology
- Physiology of AAT
- Structure of the AAT molecule (1)
- Alpha-1 antitrypsin molecule
- Function of the AAT molecule (1)
- Function of the AAT molecule (2)
- Structure of the AAT molecule (2)
- Mechanism of loop-sheet polymerization
- Polymer of Z-type alpha 1-antitrypsin molecules
- Liver biopsy
- Genetics of alpha-1 antitrypsin deficiency
- Protective threshold serum value
- Alpha 1-antitrypsin deficiency serum levels
- Clinical features of AAT deficiency (1)
- Clinical features of AAT deficiency (2)
- Design of the AAT deficiency registry
- Cumulative enrollment in AAT deficiency registry
- AAT deficiency registry: Sex and race
- AAT deficiency registry: Age
- AAT deficiency registry: Employment
- AAT levels by phenotype
- Lung functions test results
- FEV1 percent of predicted normal
- Self reported medical history of patients
- AAT deficiency registry: Symptom history
- Smoking accelerates onset of dyspnea
- FEV1 percent of predicted by smoking
- Natural history of AAT deficiency
- 30 year follow-up of AAT deficient individuals (1)
- 30 year follow-up of AAT deficient individuals (2)
- 32 year follow-up of AAT deficient individuals (1)
- 32 year follow-up of AAT deficient individuals (2)
- FEV1 slope values by smoking status
- Natural history of AAT deficiency (PI*ZZ)
- AAT deficiency registry: Overall mortality
- Mortality rate by initial percent predicted
- Underlying causes of death
- Death causes among never smokers with AAT
- Diagnosis of AAT deficiency
- Classic chest radiograph
- A cut from the upper chest
- A lower cut from the chest
- Clinical features that should prompt suspicion (1)
- Clinical features that should prompt suspicion (2)
- Recommendations for AAT testing (1)
- Recommendations for AAT testing (2)
- Recommendations for AAT testing (3)
- Treatment of AAT deficiency
- Efficacy criteria for augmentation therapy
- Therapy for alpha 1-antitrypsin deficiency
- Studies of efficacy of augmentation therapy
- Efficacy of intravenous augmentation therapy (1)
- Efficacy of intravenous augmentation therapy (2)
- Efficacy of intravenous augmentation therapy (3)
- Conclusions of clinical efficacy of augmentation (1)
- Conclusions of clinical efficacy of augmentation (2)
- New and emerging treatments for AAT (1)
- New and emerging treatments for AAT (2)
- ATT: conclusions (1)
- ATT: conclusions (2)
Topics Covered
- Epidemiology
- Pathophysiology
- Clinical testing
- Clinical features
- Natural history
- Therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Stoller, J. (2012, September 9). Alpha-1 antitrypsin deficiency: state of the art [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 30, 2024, from https://doi.org/10.69645/EEBY1176.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jamie Stoller, Consultant: Talecris/Grifols, Baxter, CSL Behring, Kamada ; Other: Have given grand rounds lectures supported by Takecris/Grifols, CSL Behring, Baxter.
